Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer | New England Journal of Medicine
商品説明・詳細
送料・お届け
商品情報
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer | New England Journal of Medicine,First-Line Pembrolizumab Monotherapy for Advanced NSCLC With Programmed Death-Ligand 1 Expression Greater Than or Equal to 50%: Real-World Study Including Older Patients in Japan - JTO Clinical and Research Reports,Efficacy | ZEJULA (niraparib) for HCPs,IMbrave150 efficacy results: Coprimary endpoints | TECENTRIQ® (atezolizumab),Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin's Lymphoma | New England Journal of Medicine